Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 16/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21735576 | 0.91 | NAMPT (0.37) | TLR7TLR8 | |
| SCHEMBL23917089 | 0.88 | TLR7 (0.37) | CFTRTLR7TLR8 | |
| SCHEMBL23916891 | 0.88 | TLR7 (0.38) | CFTRTLR7TLR8 | |
| SCHEMBL21735570 | 0.86 | JAK1 (0.40) | CFTRTLR7TLR8 | |
| SCHEMBL23917097 | 0.85 | TLR7 (0.36) | TLR7TLR8 | |
| SCHEMBL23916913 | 0.81 | TLR7 (0.36) | TLR7TLR8 | |
| SCHEMBL29314661 | 0.80 | CFTR (0.40) | CFTRTLR7TLR8MAPT | |
| SCHEMBL23917055 | 0.79 | TLR7 (0.39) | TLR7TLR8 | |
| SCHEMBL26783893 | 0.78 | CFTR (0.40) | CFTRMAPTTACR3MEN1KMT2A | |
| SCHEMBL23917096 | 0.78 | KDM4E (0.39) | TLR7TLR8MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317118-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317118-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | CFTR 197/4885TLR7 236/4885TLR8 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.